Clinical trials: First Line Treatment
Colorectal Carcinoma
Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma
The purpose of this study is to exploratorily examine efficacy and safety in the participants with chemotherapy-naïve unresectable, advanced/recurrent colorectal carcinoma of Kirsten rat sarcoma-2 virus (KRAS) wild-type who have…
- Trial name
- SAPPHIRE (NCT02337946)
- Testing
- oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
- Where
- 49 sites in Japan
- Volunteers
- 164 people
- Sponsor
- Takeda
Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
This study is carried out to see how Caucasian patients with lung cancer which has EGFR mutation will respond to gefitinib (IRESSA™) as a first line treatment.
- Trial name
- IFUM (NCT01203917)
- Testing
- Gefitinib
- Where
- 61 sites in Bulgaria, France and 11 more
- Volunteers
- 1,060 people
- Sponsor
- AstraZeneca
Uterine Neoplasms
Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer
Primary: To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline. Secondary: To assess the safety and tolerability of oxaliplatin To assess time to progression and…
- Trial name
- NCT00782041
- Testing
- Oxaliplatin, 5-FluoroUracil, Folinic acid
- Where
- Thailand
- Volunteers
- 11 people
- Sponsor
- Sanofi
Carcinoma, Non-Small-Cell Lung
Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
This is Phase 2, open label, multi-center study to assess safety and efficacy of vactosertib in combination with pembrolizumab as 1st line treatment for subjects with advanced or metastatic, PD-L1 positive, non-small cell lung…
- Trial name
- NCT04515979
- Testing
- Vactosertib 300 mg BID and pembrolizumab 200 mg IV
- Where
- South Korea
- Volunteers
- 11 people
- Sponsor
- MedPacto, Inc.
Primary Immune Thrombocytopenia (ITP)
A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.
The purpose of this study is to assess the efficacy, safety and pharmacokinetics (PK) of ianalumab (VAY736) in addition to eltrombopag treatment; and to inform the dose of ianalumab in pediatric patients (5 to <18 years of age)…
- Trial name
- VAYHIT-P (NCT07660172)
- Testing
- Ianalumab, Eltrombopag
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer - Non Small Cell Squamous, Lung Cancer - Non Small Cell Non-Squamous
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
The study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer.
- Trial name
- NCT07353957
- Testing
- Petosemtamab + Pembrolizumab
- Where
- 24 sites in United States, Australia and 5 more
- Sponsor
- Merus B.V.
Hodgkin Disease
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with…
- Trial name
- CheckMate 744 (NCT02927769)
- Testing
- Nivolumab, brentuximab vedotin, bendamustine
- Where
- 79 sites in United States, Canada and 9 more
- Volunteers
- 72 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva and gemcitabine, and of gemcitabine monotherapy, as first line treatment of elderly patients, or patients with ECOG performance status of…
- Trial name
- NCT00940875
- Testing
- erlotinib [Tarceva], gemcitabine
- Where
- 17 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Afrezza® INHALE-1 Study in Pediatrics
INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart, insulin lispro or insulin glulisine…
- Trial name
- INHALE-1 (NCT04974528)
- Testing
- Afrezza, Rapid-acting Insulin Analog, Basal Insulin
- Where
- 39 sites in United States
- Volunteers
- 319 people
- Sponsor
- Mannkind Corporation
First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.
- Trial name
- MACS1295 (NCT01129336)
- Testing
- Zoledronic acid, Standard Therapy
- Where
- 33 sites in United States
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer Metastatic
Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer
Primary Objective: Efficacy: To assess the progression-free survival rate at 10 months in patients on maintenance therapy with capecitabine plus aflibercept.
- Trial name
- Drop and Go (NCT02085005)
- Testing
- Capecitabine, Aflibercept AVE0005, Oxaliplatin SR96669
- Sponsor
- Sanofi
Nonsquamous Non-small Cell Lung Cancer
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
The purpose of this study is to identify the recommended dose of vudalimab to be used in combination with chemotherapy (Part 1) and to evaluate the efficacy and safety of vudalimab plus standard of care chemotherapy relative to…
- Trial name
- NCT06173505
- Testing
- Vudalimab + Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
- Where
- 17 sites in United States, Belgium and 6 more
- Volunteers
- 28 people
- Sponsor
- Xencor, Inc.
Colon Cancer, Rectal Cancer
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
- Trial name
- FC-4 (NCT00845039)
- Testing
- Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company
Non-Hodgkin's Lymphoma
Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma
The treatment being investigated is a patient- and tumor-specific therapy known as a personalized active immunotherapy. Personalized active immunotherapy is an attempt to use a person's own immune system to combat disease.
- Trial name
- NCT00510471
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine
- Where
- 9 sites in United States
- Sponsor
- Genitope Corporation
Advanced Non-small Cell Lung Cancer
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants
This multi-year cohort study will assess the real-world safety and effectiveness of first Line (1L) treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC participant subgroups defined…
- Trial name
- NCT06269133
- Testing
- REGN2810, Platinum-doublet chemotherapy
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Hepatocellular Carcinoma
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)
This study aims to evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab combined with Bevacizumab for the first-line treatment of advanced HCC (KYLIN-02).
- Trial name
- NCT06618664
- Testing
- SHR-8068, Adebrelimab, Bevacizumab
- Where
- China
- Volunteers
- 590 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Colorectal Cancer
Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer
This is a multicenter study designed to evaluate the response rate of S-1 plus Leucovorin (1 week on and 1 week off) as first -line treatment for patients with metastatic colorectal cancer.
- Trial name
- NCT00891332
- Testing
- S-1 plus LV (The combination therapy of S-1 and Leucovorin)
- Where
- 6 sites in China, Japan
- Volunteers
- 73 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Head and Neck Squamous Cell Carcinoma
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed…
- Trial name
- STELLAR-305 (NCT06082167)
- Testing
- Zanzalintinib, Pembrolizumab
- Where
- 168 sites in United States, Argentina and 24 more
- Volunteers
- 600 people
- Sponsor
- Exelixis
Ovarian Carcinoma, Peritoneal Carcinoma
Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer
The purposes of this study are to determine: 1) if treatment with interferon gamma-1b plus standard chemotherapy (carboplatin and paclitaxel) can increase the overall survival of patients with advanced ovarian or primary…
- Trial name
- NCT00047632
- Testing
- Interferon gamma-1b
- Where
- United States
- Volunteers
- 847 people
- Sponsor
- InterMune
Non-Squamous Non-Small Cell Neoplasm of Lung
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC
This is a randomized, multicenter, double-blind placebo-controlled phase 3 study of efficacy and safety of BCD-100 in combination with pemetrexed+cisplatin/carboplatin compared to placebo in combination with…
- Trial name
- DOMAJOR (NCT03912389)
- Testing
- BCD-100, Pemetrexed, Cisplatin (or carboplatin)
- Where
- 37 sites in Czechia, Georgia and 4 more
- Volunteers
- 292 people
- Sponsor
- Biocad